Table 3.
Univariate and multivariate analysis of engraftment
| Categories | Neutrophils ≥500 | Reticulocytes ≥1% | Platelets ≥50,000 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | |||||||
| HR | P value | HR | P value | HR | P value | HR | P value | HR | P value | HR | P value | |
| Hepcidin | ||||||||||||
| <35 ng/mL | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| ≥35 ng/mL | 1.04 | 0.79 | 1.02 | 0.9 | 0.91 | 0.55 | 0.89 | 0.49 | 0.59 | 0.003 | 0.62 | 0.008 |
| Age (years) | ||||||||||||
| <50 | 1 | 1 | 1 | |||||||||
| ≥50 | 1.02 | 0.92 | 1.04 | 0.83 | 1.03 | 0.85 | ||||||
| Sex | ||||||||||||
| Male | 1 | 1 | 1 | 1 | ||||||||
| Female | 1.01 | 0.95 | 1.06 | 0.71 | 1.36 | 0.077 | 1.44 | 0.037 | ||||
| Disease | ||||||||||||
| Myeloid | 1 | 1 | 1 | |||||||||
| Lymphoid | 1.1 | 0.57 | 1.22 | 0.25 | 0.91 | 0.59 | ||||||
| Risk | ||||||||||||
| Standard | 1 | 1 | 1 | 1 | ||||||||
| High | 0.8 | 0.17 | 0.94 | 0.7 | 0.65 | 0.021 | 0.67 | 0.031 | ||||
| Sources of stem cells | ||||||||||||
| HLA‐matched related | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| HLA‐mismatched related | 1.09 | 0.79 | 1.08 | 0.82 | 1.22 | 0.56 | 1.26 | 0.58 | 0.13 | 0.7 | 0.33 | |
| Unrelated BM/PB | 0.99 | 0.98 | 0.99 | 0.96 | 1.2 | 0.42 | 1.21 | 0.4 | 0.77 | 0.25 | 0.85 | 0.49 |
| Unrelated CB | 0.55 | 0.014 | 0.55 | 0.013 | 0.47 | 0.003 | 0.48 | 0.003 | 0.36 | <0.001 | 0.37 | <0.001 |
| ABO matching | ||||||||||||
| Matched | 1 | 1 | 1 | |||||||||
| Mismatched | 1.14 | 0.43 | 0.85 | 0.35 | 0.99 | 0.96 | ||||||
| Conditioning | ||||||||||||
| Myeloablative | 1 | 1 | 1 | |||||||||
| Reduced | 1.16 | 0.34 | 1.12 | 0.5 | 1.09 | 0.63 | ||||||
| GVHD prophylaxis | ||||||||||||
| Tacrolimus | 1 | 1 | 1 | |||||||||
| Cyclosporine | 1.02 | 0.93 | 0.71 | 0.17 | 1.05 | 0.84 | ||||||
The Cox proportional‐hazard model was applied to calculate hazard ratios (HRs) and P values. P values <0.05 are shown in bold‐type. HLA, human leukocyte antigen; BM, bone marrow; PB, peripheral blood; CB, cord blood; GVHD, graft‐versus‐host disease; tacrolimus‐based, tacrolimus with or without other agents; cyclosporine‐based, cyclosporine with or without other agents.